What disease states can cause Hemolytic Uremic Syndrome (HUS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Disease States Associated with Hemolytic Uremic Syndrome (HUS)

Hemolytic uremic syndrome (HUS) primarily occurs in two major disease states: Shiga toxin-producing infections (typical HUS) and complement-mediated disorders (atypical HUS), with several other secondary causes also recognized.

Primary Classifications of HUS

1. Typical HUS (Shiga Toxin-Associated)

  • Shiga toxin-producing Escherichia coli (STEC) infections

    • Most commonly E. coli O157:H7 1
    • Other important non-O157 STEC serogroups: O26, O45, O103, O111, O121, O145 1
    • Characterized by prodromal bloody diarrhea followed by HUS development 4-5 days after diarrhea onset 2
    • Accounts for approximately 90% of pediatric HUS cases 3
  • Shigella dysenteriae type 1 infection (also produces Shiga toxin) 2

2. Atypical HUS (aHUS)

  • Complement-mediated disorders
    • Genetic mutations in complement regulatory proteins (identified in ~60% of cases) 4
    • Deficiencies in:
      • Factor H
      • Membrane cofactor protein
      • Von Willebrand factor-cleaving protease (ADAMTS 13)
      • Intracellular vitamin B12 metabolism 3
    • Both autosomal recessive and dominant inheritance patterns 3

Secondary Causes of HUS

3. Infection-Associated (Non-STEC)

  • Streptococcus pneumoniae infections 3
  • HIV infections 3

4. Drug-Induced HUS

  • Calcineurin inhibitors (post-transplantation) 3
  • Other medications that can trigger HUS include certain chemotherapeutic agents and immunosuppressants

5. Autoimmune Disease-Associated HUS

  • Systemic lupus erythematosus 3
  • Catastrophic antiphospholipid syndrome 3

Clinical Presentation and Diagnosis

HUS is characterized by the classic triad of:

  1. Microangiopathic hemolytic anemia
  2. Thrombocytopenia
  3. Acute renal injury 5

Diagnostic criteria include:

  • Anemia with microangiopathic changes (schistocytes, burr cells, helmet cells)
  • Renal injury with hematuria, proteinuria, or elevated creatinine
  • Low platelet count (usually detected early but may normalize) 2

Key Distinctions Between Types

  • Typical HUS (STEC-associated):

    • Usually follows bloody diarrhea
    • More common in children
    • Generally better prognosis with supportive care 4
  • Atypical HUS:

    • Often no preceding diarrhea (D-HUS)
    • Relapsing course
    • 50% progress to end-stage renal disease

    • Higher mortality rate 4

Management Considerations

  • Supportive care remains the mainstay of treatment for typical HUS 5
  • Antibiotics are generally avoided in STEC infections as they may increase HUS risk 1
  • For atypical HUS, therapy is directed toward the underlying cause 3
  • Complement blockade therapy is being studied for atypical HUS, though evidence for STEC-HUS is lacking 5

Prevention

Prevention of typical HUS focuses on preventing primary STEC infection through:

  • Proper cooking of ground meats
  • Consuming only pasteurized dairy products and juices
  • Proper hand hygiene
  • Preventing cross-contamination during food preparation 1

Early recognition and prompt diagnosis are essential for optimal management of all forms of HUS to reduce morbidity and mortality.

References

Guideline

Diagnosis and Management of Gastrointestinal Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Haemolytic uraemic syndrome: an overview.

Nephrology (Carlton, Vic.), 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.